If you've been on an antidepressant for weeks or months and still don't feel like yourself, you're not alone. Research shows roughly 50–60% of patients don't achieve full remission on their first antidepressant. For years, the main options for "augmentation" — adding a second medication — meant atypical antipsychotics like Abilify (aripiprazole) or Rexulti (brexpiprazole), both effective but carrying significant metabolic and weight-gain risks.
That changed on November 6, 2025, when the FDA approved Caplyta (lumateperone) as an adjunctive (add-on) therapy for adults with major depressive disorder (MDD). It's a genuinely new option — and one worth understanding.
What Is Caplyta?
Caplyta is a novel antipsychotic originally approved for schizophrenia and bipolar depression. Its MDD approval makes it the newest FDA-approved augmentation agent for treatment-resistant depression. It's manufactured by Johnson & Johnson (which acquired Intra-Cellular Therapies).
The dose for MDD is simple: 42 mg, once daily, by mouth. It can be taken with or without food, though taking it with food improves absorption.
How Does Caplyta Work?
Caplyta has a unique mechanism of action that differentiates it from other augmentation options:
- 5-HT2A serotonin receptor antagonist — helps regulate mood signaling beyond what SSRIs/SNRIs achieve alone
- Dopamine D2 partial agonist — modulates dopamine without the overstimulation that causes akathisia (the restlessness associated with Abilify)
- Dopamine and serotonin transporter modulation — additional fine-tuning of neurotransmitter balance
This multi-target approach may explain why it works where single-mechanism drugs plateau.
Clinical Trial Results: The Numbers
The pivotal Phase 3 trial data is compelling:
- Remission rate: 25.5% (Caplyta + antidepressant) vs. 13.6% (placebo + antidepressant) — nearly double
- 6-month remission: 65% of patients in the Caplyta group achieved sustained remission
- Speed: Significant improvement on HAM-D depression scores within 2 weeks
- Sustained benefit: Continued gains through 8 weeks and beyond
For context, these remission rates are on par with or better than Abilify and Rexulti in comparable trials — but with a meaningfully better side-effect profile.
Who Is Caplyta For?
Caplyta is specifically indicated for adults with MDD who have not achieved adequate response to at least one adequate antidepressant trial. You might be a candidate if:
- You've been on an SSRI or SNRI for 6–8+ weeks at a therapeutic dose and still have significant symptoms
- Your depression improved partially but you haven't reached remission
- You've tried switching antidepressants but keep hitting the same ceiling
- You're concerned about weight gain from other augmentation options
- Previous augmentation with Abilify caused akathisia or restlessness
Side Effects
Common side effects (≥5% incidence in trials):
- Dry mouth
- Fatigue
- Tremor
- Somnolence (drowsiness)
- Dizziness
- Nausea
The standout advantage: Caplyta has a favorable metabolic profile. Unlike Abilify and many other atypical antipsychotics, it does not cause significant weight gain, hyperglycemia, or lipid abnormalities. For patients already dealing with metabolic concerns, this is a major differentiator.
Caplyta vs. Abilify vs. Rexulti: Head-to-Head
| Feature | Caplyta | Abilify | Rexulti |
|---|---|---|---|
| FDA approved for MDD | Yes (2025) | Yes (2007) | Yes (2015) |
| Weight gain | Minimal | Moderate | Low-moderate |
| Akathisia (restlessness) | Low | High (common complaint) | Low-moderate |
| Metabolic impact | Minimal | Significant | Mild |
| Sexual side effects | Low | Low | Low |
| Dose | 42 mg once daily | 2-15 mg once daily | 0.5-3 mg once daily |
| Generic available | No | Yes | No |
Cost and Insurance
Caplyta's average retail price is approximately $1,200–$1,500/month without insurance. However:
- Most commercial insurance plans cover it (check your formulary)
- Johnson & Johnson offers a copay savings card that can reduce costs to as low as $15/month for eligible patients
- Patient assistance programs are available for uninsured patients
If cost is a barrier, talk to your prescriber about prior authorization or manufacturer support.
How to Talk to Your Doctor
If you think Caplyta might be right for you, bring these questions to your next appointment:
- "I've been on [current medication] for [X weeks] and I'm still struggling — am I a candidate for augmentation?"
- "I'm concerned about weight gain with other options. Can we try Caplyta?"
- "What's the expected timeline to see improvement?"
- "How will we monitor for side effects?"
The Bottom Line
Caplyta represents a genuine advance in depression treatment. It's not a miracle drug — no medication is — but its combination of strong efficacy data and a favorable side-effect profile makes it a compelling first-choice augmentation option for 2026. If your current antidepressant isn't getting you to remission, it's worth discussing with your psychiatrist.
For more guidance on safely adding or switching medications, read our Complete Guide to Switching Antidepressants.
This article is for informational purposes only and does not constitute medical advice. Always consult your prescriber before starting, stopping, or changing any medication. If you are in crisis, contact the 988 Suicide & Crisis Lifeline by calling or texting 988.